Confirming The Value of Early Docetaxel in Men With Metastatic Hormone-Sensitive Prostate Cancer

Docetaxel combined with ADT, in men with hormone sensitive prostate cancer, when prescribed as per a study’s protocol led to significantly longer overall survival as well as other positive effects in men with metastatic hormone-sensitive prostate cancer who received only ADT.